First Surgeries Using Endologix’s DETOUR System for Complex PAD

Endologix announced the first patients underwent percutaneous transmural arterial bypass (PTAB) using the company’s DETOUR system.
 
DETOUR earned FDA approval last month, and this marks the start of its targeted U.S. market release. Using DETOUR to treat complex peripheral arterial disease (PAD), physicians can bypass lesions in the superficial femoral artery using stents routed through the femoral vein to restore blood flow to the leg. The approach is effective for patients with lesions 20-46 cm in length, those that have already had failed endovascular procedures, to those that might be suboptimal candidates for open surgical bypass.
 

Endologix worked with two renowned healthcare systems to perform the PTAB procedure using DETOUR: Cleveland Clinic’s Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute and at Salinas Valley Health Medical Center.
 
“We are delighted to be able to introduce PTAB using the DETOUR System into clinical use,” Matt Thompson, MD, president and CEO of Endologix told the press. “The DETOUR System is a pivotal addition to our product portfolio, which now offers differentiated therapies for both abdominal aortic aneurysms and PAD. The successful introduction at these leading institutions underscores our commitment to continuing to innovate on behalf of patients. Broadening our therapeutic profile is a key achievement as we transform Endologix into a leading interventional vascular company.”
 
Last month, Endologix also released 24-month data from its DETOUR2 study showing encouraging results for the PTAB procedure using DETOUR.